Compare RCUS & FCPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | FCPT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2018 | N/A |
| Metric | RCUS | FCPT |
|---|---|---|
| Price | $22.00 | $24.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $28.89 | $27.80 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 02-24-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 5.91% |
| EPS Growth | N/A | ★ 0.94 |
| EPS | N/A | ★ 1.08 |
| Revenue | $240,000,000.00 | ★ $286,803,000.00 |
| Revenue This Year | N/A | $12.16 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | ★ N/A | $22.97 |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $6.50 | $22.78 |
| 52 Week High | $26.40 | $29.81 |
| Indicator | RCUS | FCPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 72.10 |
| Support Level | $20.59 | $24.18 |
| Resistance Level | $23.40 | $24.97 |
| Average True Range (ATR) | 1.39 | 0.41 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 32.38 | 94.52 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.